Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Mufemilast by Tianjin Hemay Pharmaceutical for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
Mufemilast is under clinical development by Tianjin Hemay Pharmaceutical and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According...
Data Insights
Mufemilast by Tianjin Hemay Pharmaceutical for Ankylosing Spondylitis (Bekhterev's Disease): Likelihood of Approval
Mufemilast is under clinical development by Tianjin Hemay Pharmaceutical and currently in Phase II for Ankylosing Spondylitis (Bekhterev's Disease). According...